In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Validation of peripheral arterial tonometry as diagnostic procedure for detection of sleep disordered breathing in patients with chronic heart failure

Session Poster session 1 Saturday 08:30 -17:30

Speaker Christoph Schoebel

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P229

Authors : C Schoebel (Berlin,DE), M Stern (Berlin,DE), M Renelt (Berlin,DE), I Fietze (Berlin,DE), G Baumann (Berlin,DE), K Stangl (Berlin,DE), T Penzel (Berlin,DE)


C Schoebel1 , M Stern1 , M Renelt1 , I Fietze1 , G Baumann1 , K Stangl1 , T Penzel1 , 1Charité - Universitätsmedizin Berlin, Campus Mitte, CC11, Dept. for Cardiology, Sleep Medicine - Berlin - Germany ,

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 46

Background: This study examines the validation of a portable device using peripheral arterial tonometry (PAT) as a measurement of SDB in patients with heart failure especially in patients with chronic heart failure (CHF). A high prevalence (about 70%) of SDB in patients with heart failure is known. While 36% of CHF-patients are suffering from obstructive sleep apnea (OSA), 40% are diagnosed with central sleep apnea (CSA).

Patients and Methods: For validation of the PAT device 20 patients with CHF are investigated. PAT measurements are additionally performed within a scheduled polysomnographic examination (PSG). PAT recording is used in diagnostic night and therapeutic night. Data of both measurements (PSG and PAT) will be analyzed and compared in reference to specific types of SDB. Thus, it shall be shown that PAT can detect therapy evoked changes in apnea-hypopnea-index (AHI), oxygen-desaturation-index (ODI) and oxygen saturations.

Results: At this point 11 patients with CHF are examined. All of them are diagnosed with SDB, detected by both PSG and PAT. In particular, seven patients had primarily OSA, while four patients had primarily shown CSA. This was only detected by PSG.

Discussion: So far it seems likely that PAT examination can detect SDB in patients with CHF, but it is not able to distinguish between OSA and CSA. Furthermore it shall be investigated if accurate detection of SDB by PAT depends on type of CHF (heart failure with reduced ejection fraction = HFREF versus heart failure with preserved ejection fraction = HFPEF). Additionally, it shall be analyzed if haemodynamic changes under therapy can be seen in PAT's raw data.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are